Status:
TERMINATED
Inflammatory Bowel Disease(IBD), Treatment Response
Lead Sponsor:
University of Southern Denmark
Collaborating Sponsors:
Odense University Hospital
Hospital of Southern Jutland
Conditions:
Inflammatory Bowel Diseases
Ulcerative Colitis
Eligibility:
All Genders
18+ years
Brief Summary
Inflammatory bowel diseases (IBD) is treated with biologics targeting the pro-inflammatory molecule tumour necrosis factor-α (TNF), i.e. TNF inhibitors. Up to one third of the patients do, however, no...
Detailed Description
Inflammatory bowel diseases \[IBD\] (of which Crohn's disease (CD) and ulcerative colitis (UC) are the two most prevailed entities) is a disease of the immune system that are managed with biological a...
Eligibility Criteria
Inclusion
- diagnosed with inflammatory bowel disease
- initiation of targeted therapy
- able to read and understand Danish
Exclusion
- Patients with cancer
- Not mentally able to reply the questionnaire
Key Trial Info
Start Date :
February 8 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2024
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT05350644
Start Date
February 8 2022
End Date
June 30 2024
Last Update
December 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Odense University Hospital
Odense, Denmark, Denmark, 5000